Looking to Increase Sales of Opera System, PerkinElmer Pushes Lower-Priced LX | GenomeWeb
PerkinElmer plans to sell a less-expensive version of its newly acquired Opera technology, the Opera LX, CEO Greg Summe said during the company’s third-quarter earnings conference call last week.
 
“One of the things we need to do is take the price down on the Opera, and so we have got an R&D project that significantly takes costs and makes that a lower-priced model,” Summe said.
 
Company officials said the LX costs between 16 percent and 37 percent below the “full-blown” Opera system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.